UNSPSC 51351906: Moxestrol

This classification denotes a therapeutic estrogen with the molecular formula C21H26O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6923NT44OW, chemically known as 19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol, 11-methoxy-, (11-beta,17-alpha)- (9ci) but generally known as moxestrol, which bears US NIH Compound Identifier 71714. European Medicines Agency schedules Moxestrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14601MIG.

UNSPSC 51351906 Moxestrol is a Commodity code for a specific pharmaceutical ingredient that state and local procurement offices acquire primarily through cooperative purchasing agreements for multi-source generic drug programs. The recent activity under this code centers on cooperative multi-state pharmaceutical procurement, where jurisdictions source generic medications and over-the-counter products through established wholesaler networks rather than direct single-vendor relationships. State and local governments—including health departments, correctional facilities, and social-service agencies—use this code when procuring pharmaceutical active ingredients and finished generic products to support patient care, preventive health programs, and institutional dispensaries. The issuing body mix leans heavily toward cooperative purchasing alliances that aggregate demand across multiple states and municipalities; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the primary vehicle for recent solicitations under this code.

The geographic footprint of recent activity spans at least Minnesota and Oregon, with MMCAP representing a multi-state coalition. On January 20, 2026, MMCAP issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026; the contract term runs two years for new responders, with optional extensions through June 30, 2028 for incumbents. Vendors must supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), maintain minimum insurance coverage of $5,000,000 general liability and $2,000,000 network security and privacy liability, and comply with cGMP certification and Drug Supply Chain Security Act requirements. Price competitiveness carries 75 percent of the evaluation weight, while fixed pricing, administrative compliance, EDI capability, and willingness to accept a 3 percent administrative fee split the remaining 25 percent. Products must be available in the marketplace by May 15, 2026, when awarded vendors are provided to wholesalers for July 1, 2026 contract effectiveness.